Literature DB >> 24657823

Controlling the droplet size of formulations nebulized by vibrating-membrane technology.

Moritz Beck-Broichsitter1, Marie-Christine Knuedeler2, Werner Seeger2, Thomas Schmehl2.   

Abstract

Manipulation of aerosol characteristics is of special interest for pulmonary therapy, as a suitable particle size optimizes pulmonary deposition. The present study investigated the impact of formulation variables on the aerodynamic particle diameter (d(a)) when nebulized by vibrating-membrane technology. Membranes implemented in the Aeroneb® Pro and eFlow®rapid nebulizer revealed difference in metal composition and nozzle morphology as determined by energy dispersive X-ray measurements and scanning electron microscopy. Laser diffraction analysis of generated aerosol droplets identified the conductivity and dynamic viscosity of formulations as parameters with significant influence on the d(a) for both nebulizers. Accordingly, sample supplementation with particular excipients (conductivity: >50 μS/cm, dynamic viscosity: >1.5 mPa s) facilitated a reduction of the d(a) from ⩾8 μm, which is clearly in conflict with inhalative drug delivery, to respirable d(a) as small as ~3 μm. Overall, controlling the d(a) of formulations nebulized by vibrating-membrane technology seems to be technical feasible by an adequate adaption of samples' physicochemical properties. The Aeroneb® Pro and eFlow®rapid device are both qualified for the production of respirable aerosol clouds from specified formulations.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aerodynamic diameter; Aerosol optimization; Formulation variables; Inhalation; Pulmonary drug delivery; Vibrating-membrane nebulizer

Mesh:

Substances:

Year:  2014        PMID: 24657823     DOI: 10.1016/j.ejpb.2014.03.006

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  1 in total

1.  First Steps to Develop and Validate a CFPD Model in Order to Support the Design of Nose-to-Brain Delivered Biopharmaceuticals.

Authors:  Lucas Engelhardt; Martina Röhm; Chrystelle Mavoungou; Katharina Schindowski; Annette Schafmeister; Ulrich Simon
Journal:  Pharm Res       Date:  2016-02-17       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.